loader from loading.io

Aducanumab and the Business of Alzheimer Disease; Implicit Light Sensitivity in Migraine

Neurology® Podcast

Release Date: 10/25/2021

International Headache Congress 2021; Speech Subtypes in Parkinson Disease show art International Headache Congress 2021; Speech Subtypes in Parkinson Disease

Neurology® Podcast

In the first part of the podcast, Dr. Tesha Monteith discusses the International Headache Society and European Headache Federation 2021 joint International Headache Congress with Dr. Patricia Pozo-Rosich (00:45). In the second segment, Dr. Jeff Ratliff talks with Dr. Jan Rusz about identifying speech subtypes in patients with Parkinson disease in response to long-term dopaminergic therapy (8:18).

info_outline
Dopamine Therapy in Early PD; Neurologic Disease Definitions with Immune Checkpoint Inhibitors show art Dopamine Therapy in Early PD; Neurologic Disease Definitions with Immune Checkpoint Inhibitors

Neurology® Podcast

In the first part of the podcast, Dr. Jason Crowell discusses the AAN Guideline Subcommittee's practice guideline summary on dopaminergic therapy for motor symptoms in early Parkinson disease with Dr. Anthony Lang (00:45). In the second segment, Dr. Kathryn Nevel talks with Dr. Amanda Guidon about the development of consensus disease definitions for neurologic immune-related adverse events associated with immune checkpoint inhibitors (17:04).

info_outline
Chronic Meningitis; MS Therapies and COVID-19 show art Chronic Meningitis; MS Therapies and COVID-19

Neurology® Podcast

In the first part of the podcast, Dr. Stacey Clardy discusses the causes, features, evaluation, and treatment of chronic meningeal inflammation or infection with Dr. Allen Aksamit. In the second segment (26:48), Dr. Eoin Flanagan talks with Dr. Tomas Kalincik about the associations of disease-modifying therapies with COVID-19 severity in multiple sclerosis.

info_outline
Aducanumab: What About the Patient?; Risk of Aneurysm Rupture After Stroke Thrombolysis show art Aducanumab: What About the Patient?; Risk of Aneurysm Rupture After Stroke Thrombolysis

Neurology® Podcast

In the first part of the podcast, Dr. Gregg Day discusses the importance of patient participation in the decision-making process when considering the use of aducanumab for the treatment of Alzheimer disease with Dr. Ron Petersen, Director of the Mayo Clinic Alzheimer’s Disease Center. In the second segment, Dr. Andy Southerland talks with Dr. Jyri Virta about the risk of aneurysm rupture after thrombolysis in patients with acute ischemic stroke and unruptured intracranial aneurysms.

info_outline
 Lewy Body Dementia (November 2021 Neurology Recall) show art Lewy Body Dementia (November 2021 Neurology Recall)

Neurology® Podcast

The November 2021 replay of past episodes showcases a selection of interviews focused on Lewy body dementia. This episode features interviews with Drs. Elie Matar, Simone Baiardi, and John-Paul Taylor on clinical features and management before closing in conversation with Susan Schneider Williams on her late husband Robin Williams's experience with the disease.

info_outline
Aducanumab and the Business of Alzheimer Disease; Implicit Light Sensitivity in Migraine show art Aducanumab and the Business of Alzheimer Disease; Implicit Light Sensitivity in Migraine

Neurology® Podcast

In the first part of the podcast, Dr. Jason Crowell discusses the business of Alzheimer disease and how to approach teaching patients about aducanumab with Dr. Jason Karlawish. In the second segment, Dr. Jennifer Bickel talks with Dr. Eric Kaiser about the contribution of melanopsin and cone signals to light-induced reflexive eye closure in migraine.

info_outline
Neurologic Safety of COVID-19 Vaccines; Movement Disorders in Anti-IgLON5 Disease show art Neurologic Safety of COVID-19 Vaccines; Movement Disorders in Anti-IgLON5 Disease

Neurology® Podcast

In the first part of the podcast, Dr. Jason Crowell talks with Dr. Kiran Thakur about the importance of monitoring COVID-19 vaccines for neurologic adverse events and learning from past vaccination programs. In the second segment, Dr. Jeff Ratliff interviews Dr. Carles Gaig about the frequency and types of movement disorders in patients with anti-IgLON5 disease.

info_outline
CRISPR-Cas9 for TTR Amyloidosis; Osmotic Demyelination Syndrome show art CRISPR-Cas9 for TTR Amyloidosis; Osmotic Demyelination Syndrome

Neurology® Podcast

In the first part of the podcast, Dr. Alberto Espay talks with Prof. Julian Gillmore about CRISPR-Cas9 in vivo gene editing for transthyretin amyloidosis. In the second segment, Dr. Pearce Korb discusses the long-term outcomes of osmotic demyelination syndrome in an updated cohort with Dr. Whitney Fitts.

info_outline
Peter Frampton on His Diagnosis of Myositis; Ethical Perspectives on Costly Drugs and Healthcare show art Peter Frampton on His Diagnosis of Myositis; Ethical Perspectives on Costly Drugs and Healthcare

Neurology® Podcast

In the first part of the podcast, Dr. Ted Burns interviews legendary musician Peter Frampton about his experience with inclusion body myositis and his storied career. For more with Peter Frampton, read the cover story in the October/November 2020 issue of Brain & Life, the AAN’s patient and caregiver magazine. In the second segment, Dr. Gordon Smith talks with Dr. Amy Tsou about the updated AAN Position Statement on ethical concerns raised by high drug costs.

info_outline
Thunderclap Headache (October 2021 Neurology Recall) show art Thunderclap Headache (October 2021 Neurology Recall)

Neurology® Podcast

The October 2021 replay of past episodes showcases a selection of interviews focused on thunderclap headache. This episode features Dr. Tesha Monteith in conversation with Dr. Andy Southerland and his patient, Martien Halvorson-Taylor, as well as with headache experts Drs. Jonathan Smith, Dileep Yavagal, and Alexandra Cocores.

info_outline
 
More Episodes

In the first part of the podcast, Dr. Jason Crowell discusses the business of Alzheimer disease and how to approach teaching patients about aducanumab with Dr. Jason Karlawish. In the second segment, Dr. Jennifer Bickel talks with Dr. Eric Kaiser about the contribution of melanopsin and cone signals to light-induced reflexive eye closure in migraine.